Centessa Pharmaceuticals plc American Depositary Shares - CNTA STOCK NEWS

The insomnia market is projected to expand significantly from 2023 to 2032, driven by rising awareness and an increasing number of diagnosed cases. In the US, the insomnia market reached approximately USD 5.7 billion in 2022 with around 86 million diagnosed cases across the 7MM, including the US, EU-4, UK, and Japan. Key players like Vanda Pharmaceuticals and Janssen Pharmaceutical are developing innovative therapies, including HETLIOZ and Seltorexant. While the market is expected to grow at a CAGR of 3.7%, challenges such as decreasing drug revenues and subjective diagnostic methods may hinder growth.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced an oral presentation of additional data from the open-label extension of its Phase 2a study of SerpinPC for hemophilia at the 16th Annual Congress of EAHAD on February 10, 2023. This follows positive results recently presented at the ASH Annual Meeting. CEO Saurabh Saha highlighted SerpinPC's potential as a convenient subcutaneous treatment with a favorable safety profile. The registrational program for SerpinPC aims to accelerate its availability for hemophilia B patients. Ongoing studies include PRESent-5, PRESent-2, and PRESent-3, focusing on various hemophilia types.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that its management team will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 8:00 a.m. ET. The event will be accessible via webcast, along with an archived recording available on the investor relations section of Centessa's website. The company focuses on developing transformative medicines across various stages of development, aiming to change treatment paradigms and set new standards of care for patients.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced FDA clearance of its IND application to initiate a Phase 1/2a clinical trial for LB101, a bispecific monoclonal antibody targeting solid tumors. This innovative therapy employs a conditionally tetravalent PD-L1xCD47 LockBody technology designed to enhance treatment efficacy while minimizing systemic toxicity. Centessa aims to address significant unmet needs in cancer treatment and plans to commence the trial shortly. CEO Saurabh Saha emphasized the milestone's importance in advancing their ambitious strategy for multiple LockBody candidates.

Full-Life Technologies announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer on January 16, 2023. Dr. Heeger brings over 15 years of experience in oncology clinical development, playing a key role in the development of Erbitux and leading successful clinical trials for various monoclonal antibodies. Dr. Liu, a peptide chemist, previously served as Head of Chemistry at Novo Nordisk and co-founded Focus-X, enhancing Full-Life's capabilities in radiopharmaceuticals. Both leaders are expected to accelerate the entry of targeted radiopharmaceuticals into clinical trials.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported promising long-term results for SerpinPC, an experimental treatment for hemophilia B, during the American Society of Hematology (ASH) Annual Meeting. The open-label extension (OLE) study revealed a 93% reduction in annualized bleed rates (ABR) for all bleeds and spontaneous joint bleeds at the highest dose. Importantly, no thromboembolic events or serious adverse effects were observed. The pivotal PRESent-5 study is set to commence soon, aiming to expedite SerpinPC's regulatory approval for patients with hemophilia B.

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Karen Anderson as its new Chief People Officer, a role aimed at enhancing the company’s human resources and culture strategy. With over 25 years of experience in HR across biotechnology and pharmaceuticals, Anderson previously served as Chief Human Resources Officer at Mimecast and held senior positions at Alnylam Pharmaceuticals and Pfizer. CEO Saurabh Saha emphasized Anderson's strong track record in building high-performing teams, aligning with Centessa’s mission to develop transformational medicines for patients.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its third-quarter financial results, highlighting a cash position of $444.8 million as of September 30, 2022, ensuring operational funding into 2026. The company announced three significant milestones: the advancement of the pivotal program for SerpinPC in hemophilia B with the initiation of PRESent-5, an upcoming ASH presentation on December 10, 2022, for 18-month data on SerpinPC, and an IND submission for LB101 planned for late 2022. R&D expenses increased to $36.7 million from $25.9 million year-over-year.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced new efficacy and safety data from an 18-month treatment with SerpinPC in hemophilia patients, set for oral presentation at the 64th American Society of Hematology Annual Meeting in December 2022. The Phase 2a study shows a significant reduction in annualized bleeding rates, with data supporting SerpinPC's potential as a safe subcutaneous treatment option. The study highlights a dosing regimen of 60 mg every 4 weeks followed by 1.2 mg/kg bi-weekly, with positive tolerability results.